HIV pipeline 2017: Update from IAS Paris

20 July 2017. Related: Supplements, Pipeline report, Antiretrovirals.

This page is for the IAS Update of the HIV pipeline 2017 report.

• Read the full report  • Read the summary report

The IAS 2017 conference being held in Paris from 23–26 July will include important new updates on new HIV drugs. A rapid report from the conference will be posted to this page.

The embargo for these studies is lifted on the day each study is presented.

The main studies at the conference on new HIV drugs are listed below.

Key HIV pipeline drugs at IAS 2017

(Embargoed until presented)

D/C/F/TAF FDC

Molina JM et al. Efficacy and safety of switching from boosted-protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, HIV-1-infected adults through 24 weeks: EMERALD study. Oral abstract TUAB0101.
http://programme.ias2017.org/Abstract/Abstract/4194

Bictegravir FDC

Gallant J et al. A phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naïve adults at week 48. IAS 2017, Paris. Late breaker oral abstract MOAB0105LB.
http://programme.ias2017.org/Abstract/Abstract/5783

Sax PE et al. Phase 3 randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) vs dolutegravir (DTG) + F/TAF in treatment-naïve HIV-1 positive adults: week 48 results. IAS 2017, Paris. Late breaker oral abstract MOAB0105LB.
http://programme.ias2017.org/Abstract/Abstract/5793

Doravirine

Squires K et al. Fixed dose combination of doravirine/lamivudine/TDF is non-inferior to efavirenz/emtricitabine/TDF in treatment-naïve adults with HIV-1 infection: week 48 results of the Phase 3 DRIVE-AHEAD study. IAS 2017, Paris. Oral late-breaker abstract TUAB0104LB.
http://programme.ias2017.org/Abstract/Abstract/5585

Cabotegravir/rilpivirine long-acting (LA) injections

Eron J et al. Safety and efficacy of long-acting CAB and RPV as two drug IM maintenance therapy: LATTE-2 week 96 results. IAS 2017, Paris. Late breaker oral abstract MOAX0205LB.
http://programme.ias2017.org/Abstract/Abstract/5628

Ibalizumab

Weinheimer S et al. Long-acting ibalizumab susceptibility in multi-drug resistant HIV patients. IAS 2017, Paris. Poster abstract MOPEB0352.
http://programme.ias2017.org/Abstract/Abstract/4685

Fostemsavir

Sevinsky H et al. The effect of fostemsavir on methadone and buprenorphine pharmacokinetics. IAS 2017, Paris. Poster abstract MOPEB0338.
http://programme.ias2017.org/Abstract/Abstract/3300

Magee M et al. The effect of fostemsavir on the pharmacokinetics of a combined oral contraceptive (OC) containing ethinyl estradiol (EE) and norethindrone (NE) in healthy female subjects. IAS 2017, Paris. Poster abstract MOPEB0339.
http://programme.ias2017.org/Abstract/Abstract/3312

MK-8591 – inc PrEP

Matthews RP. Single doses as low as 0.5 mg of the novel NRTTI MK-8591 suppress HIV for at least seven days. IAS 2017, Paris. Late breaker poster abstract TUPDB020.
http://programme.ias2017.org/Abstract/Abstract/5525

Markowitz M et al. Weekly oral MK-8591 protects male rhesus macaques against repeated low dose intrarectal challenge with SHIVC109P3. IAS 2017, Paris. Late breaker oral abstract MOAX0203LB.
http://programme.ias2017.org/Abstract/Abstract/5533

Elsufavirine

Bichko V et al. Pre-clinical pharmacokinetics of elsulfavirine/VM1500A long acting injectable formulations. IAS 2017, Paris. Poster abstract WEPEA0190.
http://programme.ias2017.org/Abstract/Abstract/1515